

## Company Overview

NeuBase Therapeutics, Inc. is developing its modular peptide-nucleic acid antisense oligonucleotide (PATrOL™) platform to address genetic diseases caused by mutant proteins with a single, cohesive approach. The systemically-deliverable PATrOL therapies have the potential to improve upon current gene silencing treatments by combining the advantages of synthetic approaches with the precision of antisense technologies. NeuBase intends to use its platform to address repeat expansion disorders, with an initial focus on Huntington's disease and myotonic dystrophy, as well as a variety of other genetic disorders.

## NeuBase to Present at the Jefferies London Healthcare Conference

Nov 3 2021, 4:05 PM EDT

## NeuBase to Participate at the Chardan 5th Annual Genetic Medicines Conference

Sep 28 2021, 4:05 PM EDT

## NeuBase to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Sep 15 2021, 4:05 PM EDT

## Investor Relations

LifeSci Advisors, LLC  
Dan Ferry  
1 International Place  
14th Floor  
Boston, MA 02110  
T: 617-535-7746  
[daniel@lifesciadvisors.com](mailto:daniel@lifesciadvisors.com)

## Management Team

### Dietrich A. Stephan, Ph.D.

Chairman & Chief Executive Officer, Founder

### Robert Friedlander, M.D.

Consulting Chief Medical Officer

### William Mann, Ph.D.

Chief Operating Officer

### Sandra Rojas-Caro, M.D.

Chief Medical Officer

### Anthony Rossomando, Ph.D.

Chief Technology Officer

### Robert Zamboni, Ph.D.

Chief of Preclinical Development

---

## NeuBase Therapeutics, Inc.

350 Technology Drive  
Pittsburgh, PA 15219

---

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.